KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Net Cash Flow (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Net Cash Flow for 11 consecutive years, with -$67.5 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 2342.95% to -$67.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.1 million through Dec 2025, up 88.0% year-over-year, with the annual reading at -$5.1 million for FY2025, 88.0% up from the prior year.
  • Net Cash Flow hit -$67.5 million in Q4 2025 for Fulgent Genetics, down from $29.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $188.2 million in Q1 2022 to a low of -$213.7 million in Q2 2022.
  • Historically, Net Cash Flow has averaged -$1.8 million across 5 years, with a median of $3.8 million in 2024.
  • Biggest five-year swings in Net Cash Flow: soared 2507.33% in 2021 and later tumbled 2342.95% in 2025.
  • Year by year, Net Cash Flow stood at -$50.0 million in 2021, then tumbled by 77.9% to -$89.0 million in 2022, then soared by 114.89% to $13.3 million in 2023, then tumbled by 120.86% to -$2.8 million in 2024, then crashed by 2342.95% to -$67.5 million in 2025.
  • Business Quant data shows Net Cash Flow for FLGT at -$67.5 million in Q4 2025, $29.7 million in Q3 2025, and $20.6 million in Q2 2025.